The Alzheimer's Association International Conference (AAIC) 2026 showcased remarkable advances in fluid biomarkers for Alzheimer's disease (AD) and related neurodegenerative disorders. These developments represent a paradigm shift toward minimally invasive, highly specific diagnostic and prognostic tools.
Phosphorylated tau at threonine 217 (p-Tau217) has emerged as the most specific blood-based biomarker for detecting Alzheimer's disease pathology[1]. At AAIC 2026, several key advances were highlighted:
p-Tau181 remains the most extensively validated blood biomarker for AD[2]:
Phosphorylated tau at threonine 231 (p-Tau231) shows promise for detecting earliest pathological changes[3]:
NfL as a marker of neuroaxonal damage continues to evolve[4]:
GFAP, an astrocyte activation marker, provides unique insights[5]:
Synaptic biomarkers like NPTX1 are under active investigation[6]:
This chitinase-3-like protein (also known as CHI3L1) was discussed:
AAIC 2026 featured advances in rapid testing:
Critical progress toward clinical standardization:
The AT(N) biomarker classification system continues to evolve[7]:
New approaches combining multiple markers:
The field is moving toward:
This page provides information about AAIC 2026: Fluid Biomarkers.
Palmqvist S, et al. Performance of Fully Automated Plasma p-Tau217 Assays as Screening Tests for Alzheimer Disease. JAMA Neurology. 2024. ↩︎
Karikari TK, et al. Blood phospho-tau181 as a biomarker for Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurology. 2022. ↩︎
Ashton NJ, et al. p-Tau231 as an early marker of Alzheimer's disease pathology. Nature Medicine. 2022. ↩︎
Khalil M, et al. Neurofilament light chain as a biomarker in neurology. Nature Reviews Neurology. 2020. ↩︎
Pereira JB, et al. Plasma GFAP is an early marker of amyloid-beta but not tau pathology. Brain. 2023. ↩︎
Swanson A, et al. Neuronal pentraxin 1 contributes to synaptic dysfunction in Alzheimer's disease. Acta Neuropathologica. 2021. ↩︎
Jack CR Jr, et al. AT(N): A Research Framework for Alzheimer's Disease. Alzheimer's & Dementia. 2022. ↩︎